Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

130.49USD
18 Sep 2019
Change (% chg)

-- (--)
Prev Close
$130.49
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
164,557
52-wk High
$169.43
52-wk Low
$115.36

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals PLC - QTRLY GAAP Diluted EPS Of $4.56 Adjusted Diluted EPS Of $4.05
Tuesday, 6 Aug 2019 

Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.QTRLY TOTAL REVENUES INCREASED 7% TO $534 MILLION.QTRLY GAAP DILUTED EPS OF $4.56; ADJUSTED DILUTED EPS OF $4.05.SEES 2019 REVENUES $2,070 MILLION - $2,150 MILLION.SEES 2019 TOTAL NET PRODUCT SALES $2,055 MILLION - $2,125 MILLION.SEES 2019 GAAP NET INCOME PER DILUTED SHARE $9.40 - $10.75.SEES 2019 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $14.30 - $15.00.FY2019 EARNINGS PER SHARE VIEW $14.81, REVENUE VIEW $2.09 BILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE VIEW $3.57, REVENUE VIEW $508.6 MILLION -- REFINITIV IBES DATA.  Full Article

Jazz Pharmaceuticals Buys Pan-RAF Inhibitor Program From Redx
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ACQUIRES PRE-CLINICAL PAN-RAF INHIBITOR PROGRAM FROM REDX PHARMA.JAZZ PHARMACEUTICALS PLC - REDX TO RECEIVE $3.5 MILLION UPFRONT, UP TO $203 MILLION IN MILESTONE PAYMENTS AND ROYALTIES ON FUTURE NET SALES.JAZZ PHARMACEUTICALS PLC - REDX WILL PERFORM CERTAIN PRE-CLINICAL ACTIVITIES FOR PROGRAM UNDER A SEPARATE COLLABORATION AGREEMENT WITH JAZZ.JAZZ PHARMACEUTICALS PLC - JAZZ WILL BE RESPONSIBLE FOR FURTHER DEVELOPMENT, REGULATORY ACTIVITIES AND COMMERCIALIZATION.  Full Article

Jazz Pharmaceuticals Acquires Pre-Clinical Pan-RAF Inhibitor Program From Redx Pharma
Wednesday, 10 Jul 2019 

July 10 (Reuters) - Jazz Pharmaceuticals Plc ::JAZZ PHARMACEUTICALS ACQUIRES PRE-CLINICAL PAN-RAF INHIBITOR PROGRAM FROM REDX PHARMA.JAZZ WILL PAY REDX AN UPFRONT PAYMENT OF $3.5 MILLION.REDX TO RECEIVE UP TO $203 MILLION IN MILESTONE PAYMENTS AND ROYALTIES ON FUTURE NET SALES.REDX WILL PERFORM CERTAIN PRE-CLINICAL ACTIVITIES FOR PROGRAM UNDER A SEPARATE COLLABORATION AGREEMENT WITH JAZZ.  Full Article

Jazz Pharmaceuticals Q1 GAAP Earnings Per Share $1.47
Tuesday, 7 May 2019 

May 7 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $3.67.Q1 GAAP EARNINGS PER SHARE $1.47.Q1 EARNINGS PER SHARE ESTIMATE $3.16 -- REFINITIV IBES DATA.Q1 REVENUE $508 MILLION VERSUS REFINITIV IBES ESTIMATE OF $466 MILLION.REAFFIRMED 2019 FINANCIAL GUIDANCE..  Full Article

Jazz Pharma Says Entered Into Corporate Integrity Agreement With OIG
Thursday, 4 Apr 2019 

April 4 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS PLC - DURING 2018, RECORDED $58.2 MILLION RELATED TO CIVIL SETTLEMENT AGREEMENT WITH U.S. DOJ.JAZZ PHARMACEUTICALS PLC - IN CONNECTION WITH CIVIL SETTLEMENT, COMPANY ALSO ENTERED INTO A CORPORATE INTEGRITY AGREEMENT WITH OIG.JAZZ PHARMA - CORPORATE INTEGRITY AGREEMENT REQUIRES CO TO IMPOSE CERTAIN OVERSIGHT OBLIGATIONS ON NOMINATING & CORPORATE GOVERNANCE COMMITTEE OF BOARD.JAZZ PHARMACEUTICALS PLC - AGREEMENT WITH OIG REQUIRES COMPANY TO IMPLEMENT SET OF DEFINED CORPORATE INTEGRITY ACTIVITIES FOR A PERIOD OF FIVE YEARS.JAZZ PHARMACEUTICALS - CORPORATE INTEGRITY AGREEMENT ALSO INCLUDES CERTAIN REPORTING, CERTIFICATION, RECORD RETENTION, AND NOTIFICATION REQUIREMENTS.  Full Article

Jazz Pharmaceuticals Announces Positive Top-Line Results From Phase 3 Study Of JZP-258
Tuesday, 26 Mar 2019 

March 26 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF JZP-258 IN ADULT NARCOLEPSY PATIENTS WITH CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS.JZP-258 ACHIEVES PRIMARY AND KEY SECONDARY ENDPOINTS.SAFETY PROFILE OF JZP-258 IS CONSISTENT WITH SODIUM OXYBATE.TWO PATIENTS EXPERIENCED SERIOUS ADVERSE EVENTS (SAES) THAT WERE CONSIDERED BY INVESTIGATOR TO BE TREATMENT RELATED.WILL MEET WITH FDA TO DISCUSS PHASE 3 RESULTS IN NARCOLEPSY AND NDA SUBMISSION PLANS.WILL MEET WITH FDA WITH GOAL OF MAKING JZP-258 AVAILABLE TO NARCOLEPSY PATIENTS.  Full Article

Jazz Pharmaceuticals Announces U.S. FDA Approval Of Daytime Sleepiness Drug
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES U.S. FDA APPROVAL OF SUNOSI™ (SOLRIAMFETOL) FOR EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA.JAZZ PHARMACEUTICALS PLC - SUNOSI EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. FOLLOWING FINAL SCHEDULING DECISION BY U.S. DEA.  Full Article

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FULL YEAR AND FOURTH QUARTER 2018 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $3.64.Q4 GAAP EARNINGS PER SHARE $2.64.Q4 EARNINGS PER SHARE ESTIMATE $3.02 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $2.05 BILLION TO $2.13 BILLION.QTRLY TOTAL REVENUES $476.5 MILLION VERSUS $436.4 MILLION.SEES 2019 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $14.30 TO $15.00.SEES 2019 TOTAL NET PRODUCT SALES $2,035 MILLION TO $2,110 MILLION.  Full Article

Jazz Pharmaceuticals Says Received Notice From Porton Biopharma Ltd Related To Royalty Bearing Licence Agreement And Supply Agreement
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS - RECEIVED NOTICE FROM PORTON BIOPHARMA LIMITED RELATED TO ROYALTY BEARING LICENCE AGREEMENT AND SUPPLY AGREEMENT.JAZZ PHARMACEUTICALS - NOTICE PROVIDES FOR TERMINATION OF RBLA AS OF EXPIRATION OF ITS CURRENT TERM ON DEC 31, 2020.JAZZ PHARMACEUTICALS PLC - CO & PORTON BIOPHARMA HAD BEEN ENGAGED IN DISCUSSIONS RELATED TO REPLACEMENT AGREEMENT, BUT PARTIES DID NOT REACH AGREEMENT.JAZZ PHARMACEUTICALS SAYS TO LOSE LICENSE TO SELL ERWINAZE AFTER DEC 31, 2020, EXCEPT UNDER CERTAIN TERMS FOR POST-TERMINATION PERIOD - SEC FILING.  Full Article

Jazz Pharmaceuticals Announces Q3 2018 Financial Results
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.QTRLY TOTAL REVENUES INCREASED 14% TO $469 MILLION.QTRLY GAAP DILUTED EPS OF $2.41.QTRLY ADJUSTED DILUTED EPS OF $3.58.QTRLY XYREM PRODUCT SALES INCREASED 18% TO $357 MILLION.AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $1.1 BILLION.JAZZ PHARMACEUTICALS - SEES 2018 REVENUE $1,860 MILLION - $1,900 MILLION.Q3 EARNINGS PER SHARE VIEW $3.32, REVENUE VIEW $482.6 MILLION -- THOMSON REUTERS I/B/E/S.JAZZ PHARMACEUTICALS - SEES 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.75 - $13.25.JAZZ PHARMACEUTICALS - SEES 2018 GAAP NET INCOME PER DILUTED SHARE $5.70 - $6.90.FY2018 EARNINGS PER SHARE VIEW $13.11, REVENUE VIEW $1.92 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Drugmakers Jazz, Alexion, Lundbeck to pay $123 million to resolve U.S. charity kickback probe

BOSTON Three drugmakers will pay $122.6 million to resolve claims they used charities that help cover Medicare patients' out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging use of their medications, including some expensive ones.